Glucagon R/GCGR Antibody (591929) [Janelia Fluor® 549]
Novus Biologicals, part of Bio-Techne | Catalog # FAB10296I
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
CyTOF-ready, Flow Cytometry
Label
Janelia Fluor 549
Antibody Source
Monoclonal Mouse IgG2A Clone # 591929
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
HEK293 human embryonic kidney cell line transfected with human Glucagon R/GCGR
Met1-Gln142
Accession # P47871
Met1-Gln142
Accession # P47871
Specificity
Detects human Glucagon R/GCGR in direct ELISAs.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG2A
Applications for Glucagon R/GCGR Antibody (591929) [Janelia Fluor® 549]
Application
Recommended Usage
CyTOF-ready
Optimal dilutions of this antibody should be experimentally determined.
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from hybridoma culture supernatant
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: Glucagon R/GCGR
Long Name
Glucagon Receptor
Alternate Names
GCGR, GGR, GLR, GlucagonR
Additional Glucagon R/GCGR Products
Product Documents for Glucagon R/GCGR Antibody (591929) [Janelia Fluor® 549]
Product Specific Notices for Glucagon R/GCGR Antibody (591929) [Janelia Fluor® 549]
Sold under license from the Howard Hughes Medical Institute, Janelia Research Campus.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...